Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy

[1]  C. Quinn,et al.  New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers , 2016, Virchows Archiv.

[2]  Yuzhen Han,et al.  Tumor Invasiveness, Not Lymphangiogenesis, Is Correlated with Lymph Node Metastasis and Unfavorable Prognosis in Young Breast Cancer Patients (≤35 Years) , 2015, PloS one.

[3]  E. Connolly,et al.  Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy , 2015, SpringerPlus.

[4]  G. Ball,et al.  Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer , 2014, Clinical Cancer Research.

[5]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[6]  Michael Detmar,et al.  Mechanisms of lymphatic metastasis. , 2014, The Journal of clinical investigation.

[7]  Stewart J Anderson,et al.  Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Mituś,et al.  Lymphangiogenesis assessed using three methods is related to tumour grade, breast cancer subtype and expression of basal marker. , 2012, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[9]  A. Patchefsky,et al.  Lymphatic Space Invasion is Not an Independent Predictor of Outcomes in Early Stage Breast Cancer Treated by Breast‐Conserving Surgery and Radiation , 2012, The breast journal.

[10]  I. Ellis,et al.  The prognostic significance of lymphovascular invasion in invasive breast carcinoma , 2012, Cancer.

[11]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Uematsu,et al.  Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer? , 2011, Breast cancer.

[13]  M. Park,et al.  The Role of Lymphovascular Invasion as a Prognostic Factor in Patients with Lymph Node-Positive Operable Invasive Breast Cancer , 2011, Journal of breast cancer.

[14]  E. Topuz,et al.  Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy , 2011, Oncology.

[15]  D. Steinhilber,et al.  Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. , 2011, The Journal of clinical investigation.

[16]  I. Ellis,et al.  Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance , 2011, Modern Pathology.

[17]  M. Kurosumi,et al.  Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer. , 2011, Experimental and therapeutic medicine.

[18]  I. Ellis,et al.  Objective assessment of lymphatic and blood vascular invasion in lymph node‐negative breast carcinoma: findings from a large case series with long‐term follow‐up , 2011, The Journal of pathology.

[19]  M. Dowsett,et al.  American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of oncology practice.

[20]  K. Hunt,et al.  Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy , 2009, Breast Cancer Research.

[21]  T. Shibata,et al.  Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy , 2009, Cancer science.

[22]  E. Winer,et al.  Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Ellis,et al.  Improved Methods of Detection of Lymphovascular Invasion Demonstrate That It is the Predominant Method of Vascular Invasion in Breast Cancer and has Important Clinical Consequences , 2007, The American journal of surgical pathology.

[24]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. von Minckwitz,et al.  Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. , 2007, Breast.

[27]  M. Bollet,et al.  Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study. , 2006, European journal of cancer.

[28]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R W Blamey,et al.  Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. , 2006, European journal of cancer.

[30]  G. Hortobagyi,et al.  Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[31]  Michael Gnant,et al.  Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer , 2004, Annals of surgery.

[32]  A. Vincent-Salomon,et al.  [Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors]. , 2003, Annales de pathologie.

[33]  F. Penault-Llorca,et al.  Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer , 2002, British Journal of Cancer.

[34]  T. Petit,et al.  Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  F. Kwiatkowski,et al.  Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. , 1998, American journal of clinical oncology.

[36]  S. Pinder,et al.  Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up , 1994, Histopathology.

[37]  B. Rasmussen,et al.  Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. , 2009, Journal of the National Cancer Institute.

[38]  J. Ragaz.  Preoperative (neoadjuvant) chemotherapy for breast cancer: outline of the British Columbia Trial. , 1986, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[39]  J. Ragaz,et al.  Preoperative adjuvant chemotherapy (neoadjuvant) for carcinoma of the breast: rationale and safety report. , 1985, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.